Recovery Plus Pen

PEPTIVA RECOVERY PLUS PEN is a three-peptide research blend of BPC-157, TB-500 and KPV supplied as a single 30mg/3ml pre-filled research pen. The carton states a total peptide content of 30mg per 3ml; a verified per-ingredient split is not published for this blend.

BPC-157 is a synthetic 15-amino-acid peptide whose sequence is derived from a protein found in human gastric juice. Published research is almost entirely preclinical: rat and in-vitro studies have examined tendon, ligament, muscle and gut-lining injury models. There are no completed, published human efficacy trials, and BPC-157 is not an approved medicine in any country.

TB-500 is the name commonly given to a synthetic 7-amino-acid fragment (Ac-LKKTETQ, residues 17–23) of thymosin beta-4 (Tβ4), a naturally occurring 43-amino-acid protein that binds and sequesters actin monomers. The fragment corresponds to the actin-binding region of Tβ4. Human clinical trial evidence exists only for full-length Tβ4 (for example RGN-259 eye drops in dry-eye and neurotrophic-keratopathy studies) — it does not exist for the TB-500 fragment itself, whose published evidence is biochemical, structural and preclinical.

KPV (Lys-Pro-Val) is the three-amino-acid C-terminal fragment of alpha-melanocyte-stimulating hormone (α-MSH residues 11–13). Published cell studies report that KPV enters intestinal epithelial and immune cells via the PepT1 transporter and reduces NF-κB and MAPK signalling, and mouse colitis models (DSS and TNBS) reported reduced inflammatory markers after oral KPV. These are preclinical findings; no human efficacy data have been published.

How to read this evidence. Findings described above come from laboratory and animal studies unless stated otherwise. Preclinical results do not establish effects in humans, and no claim of healing, anti-inflammatory benefit or synergy between ingredients is made for this product. This material is supplied strictly for laboratory and in-vitro research — not for human or animal use.

• BPC-157 — studied in rodent tendon, ligament, muscle and gut-lining injury models (preclinical only)
• TB-500 — thymosin beta-4 fragment covering the actin-binding region; human trial data exist only for full-length Tβ4
• KPV — alpha-MSH tripeptide studied for PepT1 uptake and NF-κB signalling in cell and mouse colitis models
• Total peptide content 30mg / 3ml as printed on the carton; per-ingredient split not published
• No human efficacy, healing or synergy claims are made — research use only

Store refrigerated at 2°C–8°C. Do not freeze. Protect from light. (As printed on the carton.)

• 1 x Pre-Filled Pen (30mg/3ml)
• 20 x 31G 5mm Needles
• 1 x Instruction Leaflet
• Verification Code Inside

Batch RCP2607A01 · Expiry 05/2029. Scan the QR on the back of the carton or verify online. Certificates of Analysis available on request by email.

Supplied strictly as a research material for laboratory and in-vitro use only. Not for human or animal use. Not a medicine, supplement or cosmetic. No information on this page constitutes dosing, administration or therapeutic guidance.